Overview
Investment Type
Venture Capital
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 13, 2012 | Cardioxyl Pharmaceuticals Raises $28M in Series B Financing | Cardioxyl Pharmaceuticals, Inc., a Chapel Hill, NC-based clinical-stage pharmaceutical company, has raised $28m in Series B financing. The round was led by OrbiMed Advisors, with participation from new investor Osage University Partners and... |
| Nov 7, 2012 | Biopharmaceutical startup developing heart failure therapeutic raises more than $28M | Solution/product: The drug development company’s lead product in its pipeline, CXL-1020 is a compound designed to treat acute decompensated heart failure, the top reason for hospitalization among adults aged 65 or older in the US. The condi... |
| Oct 27, 2011 | HyperBranch raises $1M, tests new sealant for brain, spinal surgeries | HyperBranch’s investors include Durham venture capital firm The Aurora Funds. Jeff Clark, a managing director at Aurora, is HyperBranch’s chief operating officer. HyperBranch is led by President and CEO John Conn, a medical device industry ... |
| May 1, 2009 | Argos Therapeutics sees new promise for immunotherapeutics | Learn More-External Link |
| HyperBranch raises $1M, tests new sealant for brain, spinal surgeries | Wound and surgical sealant company HyperBranch Medical Technology has developed a gel intended as a sealant for brain and spinal procedures. The company is in the midst of clinical testing to see if it works as well as a sealant from Covidi... | |
| Biopharmaceutical startup developing heart failure therapeutic raises more than $28M | Company name: Cardioxyl Pharmaceuticals Industry: Pharmaceuticals Location: Chapel Hill, North Carolina Solution/product: The drug development company’s lead product in its pipeline, CXL-1020 is a compound designed to treat acute decompensa... | |
| Biopharma startup raises $51M for therapeutic to treat bleeding complications from angioplasty | In one of the largest financing rounds this year, biopharmaceutical startup Regado Biosciences has raised $51 million to advance its anti-clotting therapeutic through Phase 3 clinical trials. A subsidiary of Russian investment firm Rusnano,... |
Reviews 0
FAQ about The Aurora Funds
What has the press written about The Aurora Funds?
Parsers VC has collected 8 articles mentioning The Aurora Funds, among them “Cardioxyl Pharmaceuticals Raises $28M in Series B Financing” (Nov 13, 2012) and “Biopharmaceutical startup developing heart failure therapeutic raises more than $28M” (Nov 7, 2012).
Is The Aurora Funds still active?
Yes, The Aurora Funds is active; its latest activity on Parsers VC dates from Dec 19, 2012.